Therefore, by targeting the IGF1-HOXA13-IGF1R oncogenic loop, a potential therapeutic strategy could be introduced to inhibit HOXA13-driven CRC metastasis [44]. This evidence concerns the gene IGF1R and colorectal carcinoma.